Back
Speaker illustration

Doctor Maria Estela Tettamanti

Alexander Fleming Institute, Buenos Aires (Argentina)

I am a clinical cardiologist. Since 2003 I moved towards the Heart Failure field: first as a Fellow Physician at Favaloro Foundation in Argentina. Later I worked on my PhD research project and thesis in Spain. From 2010 to 2014 I headed the HF and PH Unit at Austral University Hospital, ARG. I have a strong interest in the genetic aetiologies of cardiomyopathies. I completed a Master in Molecular Genetics (UBA, ARG). In 2016 I got an International Master in PH (Menendez Pelayo University, Spain) and in May 2018, the HFA of the ESC Certification in HF. Nowadays I act as a cardio - oncologist at Fleming Institute (BA, ARG). As part of a team of cardiologists, I follow up and treat patients with ventricular dysfunction associated to their cancer treatment. I am especially interested in research directed to the better understanding of the molecular and genetic issues of this entity, because its results will improve our knowledge on the subject and offer new possible solutions for patients.

Presentations

Sensitivity and specificity of strain rate for the early detection of left ventricular dysfunction in breast cancer patients receiving adjuvant treatment with adriamycin with or without trastuzumab

Event: ESC Congress 2021 - The Digital Experience

Topic: Cardio-Oncology

Session: Cardiovascular Disease in Special Populations ePosters

Access
Thumbnail

Cardiac transplantation after oncologic diseases: a case of cardiotoxic cardiomyopathy.

Event: Heart Failure 2021

Topic: Cardio-Oncology

Session: Clinical Cases: Chronic Heart Failure and Comorbidities

Access
Thumbnail

Early detection of cardiotoxicity in breast cancer patients: red flags according to a traffic lights - like coding system after long-term experience at a referral centre

Event: Heart Failure 2019

Topic: Cardio-Oncology

Session: Basic Science

Access
Thumbnail

Trastuzumab associated cardiotoxicity in breast cancer patients: a report after 4 years of follow up at a specialized centre

Event: Heart Failure 2019

Topic: Cardio-Oncology

Session: Cardiovascular Disease in Special Populations

Access
Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb